CA3165891A1 - Prophylactic and/or therapeutic agent for chronic prostatitis/chronic pelvic pain syndrome - Google Patents

Prophylactic and/or therapeutic agent for chronic prostatitis/chronic pelvic pain syndrome

Info

Publication number
CA3165891A1
CA3165891A1 CA3165891A CA3165891A CA3165891A1 CA 3165891 A1 CA3165891 A1 CA 3165891A1 CA 3165891 A CA3165891 A CA 3165891A CA 3165891 A CA3165891 A CA 3165891A CA 3165891 A1 CA3165891 A1 CA 3165891A1
Authority
CA
Canada
Prior art keywords
phenyl
chloro
ethyl
arb
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3165891A
Other languages
English (en)
French (fr)
Inventor
Ken Okamoto
Maki Kurita
Hiroshi Yamaguchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Shinyaku Co Ltd
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Publication of CA3165891A1 publication Critical patent/CA3165891A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CA3165891A 2019-12-25 2020-12-24 Prophylactic and/or therapeutic agent for chronic prostatitis/chronic pelvic pain syndrome Pending CA3165891A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019233865 2019-12-25
JP2019-233865 2019-12-25
PCT/JP2020/048479 WO2021132472A1 (ja) 2019-12-25 2020-12-24 慢性前立腺炎／慢性骨盤痛症候群の予防及び／又は治療剤

Publications (1)

Publication Number Publication Date
CA3165891A1 true CA3165891A1 (en) 2021-07-01

Family

ID=76575232

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3165891A Pending CA3165891A1 (en) 2019-12-25 2020-12-24 Prophylactic and/or therapeutic agent for chronic prostatitis/chronic pelvic pain syndrome

Country Status (16)

Country Link
US (1) US12599589B2 (https=)
EP (1) EP4082573A4 (https=)
JP (3) JP7499789B2 (https=)
KR (1) KR20220120646A (https=)
CN (2) CN119303087A (https=)
AU (1) AU2020413313B2 (https=)
BR (1) BR112022012485A2 (https=)
CA (1) CA3165891A1 (https=)
CO (1) CO2022010343A2 (https=)
EC (1) ECSP22058286A (https=)
IL (1) IL294191A (https=)
MX (1) MX2022007936A (https=)
PE (1) PE20230164A1 (https=)
PH (1) PH12022551578A1 (https=)
UA (1) UA130283C2 (https=)
WO (1) WO2021132472A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116082247B (zh) * 2023-01-19 2025-08-01 浙江工业大学 一种苯并咪唑类衍生物及其应用
CN121401398A (zh) * 2025-12-29 2026-01-27 汕头市中心医院 一种实验性自身免疫性前列腺炎大鼠模型的构建方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32470A (es) 2009-03-05 2010-10-29 Boehringer Ingelheim Int Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
WO2011023812A1 (en) 2009-08-27 2011-03-03 Novasaid Ab Microsomal prostaglandin e synthase-1 (mpges1) inhibitors
WO2011048004A1 (en) * 2009-10-23 2011-04-28 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin e2 synthase-1
TW201206440A (en) * 2010-04-28 2012-02-16 Astellas Pharma Inc Prophylactic or therapeutic agent for diseases associated with pains in urinary organs
US8759537B2 (en) 2010-08-20 2014-06-24 Boehringer Ingelheim International Gmbh 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
US8586604B2 (en) 2010-08-20 2013-11-19 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin E2 synthase-1
UY33779A (es) 2010-12-10 2012-07-31 Boehringer Ingelheim Int ?2-(fenilamino)-1H-bencimidazol-5-carboxamidas novedosas?
AR086254A1 (es) 2011-05-26 2013-11-27 Lilly Co Eli Derivados de imidazol utiles para el tratamiento de artritis
PH12014500326B1 (en) 2011-08-18 2018-01-10 Nippon Shinyaku Co Ltd Heterocyclic derivative and pharmaceutical drug
CN104039956A (zh) * 2011-11-04 2014-09-10 葛兰素史密斯克莱知识产权（第2号）有限公司 治疗方法
EP3372589B1 (en) * 2015-10-29 2021-10-20 ASKA Pharmaceutical Co., Ltd. Pyrimidine derivative

Also Published As

Publication number Publication date
ECSP22058286A (es) 2022-09-30
JP2024103724A (ja) 2024-08-01
JP2026015542A (ja) 2026-01-29
MX2022007936A (es) 2022-10-27
PE20230164A1 (es) 2023-02-01
BR112022012485A2 (pt) 2022-09-06
AU2020413313B2 (en) 2025-11-27
EP4082573A4 (en) 2024-01-10
JPWO2021132472A1 (https=) 2021-07-01
NZ789736A (en) 2025-10-31
CO2022010343A2 (es) 2022-10-31
JP7779953B2 (ja) 2025-12-03
US12599589B2 (en) 2026-04-14
US20230094705A1 (en) 2023-03-30
CN114867495A (zh) 2022-08-05
AU2020413313A1 (en) 2022-07-14
JP7499789B2 (ja) 2024-06-14
PH12022551578A1 (en) 2023-11-29
WO2021132472A1 (ja) 2021-07-01
EP4082573A1 (en) 2022-11-02
CN119303087A (zh) 2025-01-14
KR20220120646A (ko) 2022-08-30
UA130283C2 (uk) 2026-01-07
CN114867495B (zh) 2024-10-18
IL294191A (en) 2022-08-01

Similar Documents

Publication Publication Date Title
CA2780892C (en) Kinase inhibitors
RU2288222C2 (ru) Производное 2-циано-4-фторпирролидина или его соль
KR101413392B1 (ko) 단백질 키나제 억제제로서의 화합물 및 조성물
KR20230173083A (ko) Cdk 억제제 및 이의 사용 방법
HUE026671T2 (en) Heterocyclic derivatives as microsomal prostaglandin E synthetase inhibitors (mPGEs)
JP7779953B2 (ja) 慢性前立腺炎／慢性骨盤痛症候群の予防及び／又は治療剤
KR20150058257A (ko) 환형 에터 피라졸-4-일-헤테로사이클릴-카복사마이드 화합물 및 이의 사용 방법
KR20130001309A (ko) 피라졸-4-일-헤테로사이클릴-카복사마이드 화합물 및 사용 방법
WO2014105958A2 (en) Fused pyrimidine compounds and use thereof
CA2860466C (en) Use of 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
EP4587429B1 (en) Substituted oxoisoindolinyl piperidine-2,6-dione compounds
RU2836236C1 (ru) Профилактическое и/или терапевтическое средство против хронического простатита/синдрома хронической тазовой боли
HK40081072A (en) Prophylactic and/or therapeutic agent for chronic prostatitis/chronic pelvic pain syndrome
CA3165893A1 (en) Antitumor drug for use in combination with immune checkpoint inhibitor
CA2959290A1 (en) 2-aminothiazole derivative or salt thereof
US20230036867A1 (en) N-(3-(5-(pyrimidin-4-yl)thiazol-4-yl)phenyl)sulfonamide compounds and their uses as braf inhibitors
CN116323595B (zh) 作为激酶抑制剂的吡唑基-嘧啶衍生物
HK40091783B (zh) 作为激酶抑制剂的吡唑基-嘧啶衍生物
WO2025206302A1 (ja) キナゾリン化合物および医薬
CN117186097A (zh) 一种具有rsk抑制作用的羧酰胺衍生物、包含其的药物组合物及其用途
HK40091783A (zh) 作为激酶抑制剂的吡唑基-嘧啶衍生物
EA043328B1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназ

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231221

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250128

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250425

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250429

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250630

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251105

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251105